Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04455750
Title A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Alliance for Clinical Trials in Oncology
Indications

prostate adenocarcinoma

Therapies

Enzalutamide

Goserelin + Leuprolide

Enzalutamide + Rucaparib

Degarelix

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.